2022
Postprocedural Pain Associated With 5 Versus 20 Intradetrusor Injections of OnabotulinumtoxinA for Treatment of Overactive Bladder: A Multicenter Randomized Clinical Trial
Chang E, Ringel N, Woodburn K, Tanner J, Bassaly R, Greene K, Wyman A, Iglesia C. Postprocedural Pain Associated With 5 Versus 20 Intradetrusor Injections of OnabotulinumtoxinA for Treatment of Overactive Bladder: A Multicenter Randomized Clinical Trial. Obstetrical & Gynecological Survey 2022, 77: 650-651. DOI: 10.1097/ogx.0000000000001102.Peer-Reviewed Original ResearchOveractive bladderNonneurogenic overactive bladderThird-line therapyΒ-agonist therapyAmerican Urological AssociationFemale pelvic medicineSociety of UrodynamicsIntradetrusor injectionsPain AssociatedTreatment episodesClinical trialsUrological AssociationPelvic medicineBladderTherapyBehavioral changesInjectionWide variationMulticenterOnabotulinumtoxinACholinergicUrodynamicsTrialsPostprocedural Pain Associated With 5 Versus 20 Intradetrusor Injections of onabotulinumtoxinA for Treatment of Overactive Bladder: A Multicenter Randomized Clinical Trial
Chang E, Ringel N, Woodburn K, Tanner J, Bassaly R, Greene K, Wyman A, Iglesia C. Postprocedural Pain Associated With 5 Versus 20 Intradetrusor Injections of onabotulinumtoxinA for Treatment of Overactive Bladder: A Multicenter Randomized Clinical Trial. Urogynecology 2022, 28: 518-525. PMID: 35543540, DOI: 10.1097/spv.0000000000001199.Peer-Reviewed Original ResearchConceptsUrgency urinary incontinenceOveractive bladderProcedure timeIntradetrusor injectionsAdverse eventsUrinary incontinenceClinical trialsSubjective efficacyAverage pain scoreGlobal response assessmentRefractory overactive bladderIdiopathic overactive bladderVisual analog scalePain scoresOnabotulinumtoxinA treatmentPain AssociatedPain levelsWeeks postprocedurePostprocedure complicationsAnalog scaleProcedure durationResponse assessmentPatient experiencePatientsInjection paradigm
2021
Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options.
Escobar CM, Falk KN, Mehta S, Hall EF, Menhaji K, Sappenfield EC, Brown OE, Ringel NE, Chang OH, Tellechea LM, Barnes HC, Jeney SES, Bennett AT, Cardenas-Trowers OO. Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options. Obstetrics And Gynecology 2021, 137: 454-460. PMID: 33543891, DOI: 10.1097/aog.0000000000004279.Commentaries, Editorials and LettersConceptsOveractive bladderΒ3-adrenoceptor agonistHealth care inequalitiesOral medicationsFavorable side effect profileTreatment of OABAlternative oral treatmentSecond-line therapySide effect profileCare inequalitiesIdiopathic overactive bladderCognitive side effectsHealth care professionalsQuality of lifeProcedural therapiesOral treatmentEffect profileOAB medicationsTreatment algorithmTreatment optionsChronic conditionsCare professionalsSide effectsMedicationsBetter care